Nirmatrelvir-ritonavir: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
* eGFR ≥60 mL/min: no adjustment |
* eGFR ≥60 mL/min: no adjustment |
||
| − | * eGFR 30-59 mL/min: |
+ | * eGFR 30-59 mL/min: 150 mg/100 mg p.o. bid |
| − | * eGFR <30 mL/min: |
+ | * eGFR <30 mL/min: 300 mg/100 mg load on day 1, followed by 150 mg/100 mg p.o daily for 4 more days |
| + | * Dialysis: 300 mg/100 mg load on day 1, followed by 150 mg/100 mg p.o daily for 4 more days, given after dialysis on dialysis days |
||
| + | |||
| + | === Hepatic Dosing === |
||
| + | |||
| + | * [[Child-Pugh classification|Child-Pugh]] class C: contraindicated |
||
[[Category:Medications]] |
[[Category:Medications]] |
||
Latest revision as of 10:36, 24 July 2022
Dosing
- COVID-19: Nirmatrelvir/ritonavir 300 mg/100 mg p.o. bid for 5 days, started within 5 days of symptom onset
Renal Dosing
- eGFR ≥60 mL/min: no adjustment
- eGFR 30-59 mL/min: 150 mg/100 mg p.o. bid
- eGFR <30 mL/min: 300 mg/100 mg load on day 1, followed by 150 mg/100 mg p.o daily for 4 more days
- Dialysis: 300 mg/100 mg load on day 1, followed by 150 mg/100 mg p.o daily for 4 more days, given after dialysis on dialysis days
Hepatic Dosing
- Child-Pugh class C: contraindicated
